5/3
11:00 am
cdtx
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Low
Report
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
5/2
06:15 pm
cdtx
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Low
Report
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
4/26
07:09 pm
cdtx
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform [Seeking Alpha]
Low
Report
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform [Seeking Alpha]
4/26
08:06 am
cdtx
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 [Yahoo! Finance]
Low
Report
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 [Yahoo! Finance]
4/26
08:00 am
cdtx
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Low
Report
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
4/25
09:00 pm
cdtx
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
Low
Report
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
4/25
04:21 pm
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "strong-buy" rating re-affirmed by analysts at WBB Securities. They now have a $40.00 price target on the stock.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "strong-buy" rating re-affirmed by analysts at WBB Securities. They now have a $40.00 price target on the stock.
4/25
02:25 pm
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its price target raised by analysts at Needham & Company LLC from $3.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its price target raised by analysts at Needham & Company LLC from $3.00 to $25.00. They now have a "buy" rating on the stock.
4/25
11:25 am
cdtx
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
Low
Report
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
4/24
04:14 pm
cdtx
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline [Yahoo! Finance]
High
Report
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline [Yahoo! Finance]
4/24
04:14 pm
cdtx
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million [Yahoo! Finance]
High
Report
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million [Yahoo! Finance]
4/24
04:05 pm
cdtx
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
Medium
Report
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
4/24
04:01 pm
cdtx
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Medium
Report
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
4/23
09:00 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
4/22
05:21 pm
cdtx
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
4/22
05:17 pm
cdtx
Cidara Therapeutics announces receipt of Nasdaq delinquency notice [Seeking Alpha]
Medium
Report
Cidara Therapeutics announces receipt of Nasdaq delinquency notice [Seeking Alpha]
4/22
05:10 pm
cdtx
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice [Yahoo! Finance]
Medium
Report
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice [Yahoo! Finance]
4/22
05:10 pm
cdtx
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4/22
05:06 pm
cdtx
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
Low
Report
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
4/22
08:59 am
cdtx
Cidara Therapeutics Announces Reverse Stock Split [Yahoo! Finance]
Medium
Report
Cidara Therapeutics Announces Reverse Stock Split [Yahoo! Finance]
4/22
08:49 am
cdtx
Cidara Therapeutics Announces Reverse Stock Split
High
Report
Cidara Therapeutics Announces Reverse Stock Split
4/8
03:09 pm
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
4/5
03:13 pm
cdtx
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
4/5
03:00 pm
cdtx
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
Medium
Report
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
3/6
08:11 am
cdtx
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]